Ahmet Elmaağaclı

4.2k total citations
82 papers, 2.8k citations indexed

About

Ahmet Elmaağaclı is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Ahmet Elmaağaclı has authored 82 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Hematology, 26 papers in Immunology and 17 papers in Oncology. Recurrent topics in Ahmet Elmaağaclı's work include Hematopoietic Stem Cell Transplantation (35 papers), Chronic Myeloid Leukemia Treatments (24 papers) and Immune Cell Function and Interaction (15 papers). Ahmet Elmaağaclı is often cited by papers focused on Hematopoietic Stem Cell Transplantation (35 papers), Chronic Myeloid Leukemia Treatments (24 papers) and Immune Cell Function and Interaction (15 papers). Ahmet Elmaağaclı collaborates with scholars based in Germany, United States and France. Ahmet Elmaağaclı's co-authors include Dietrich W. Beelen, Michael Koldehoff, Rudolf Trenschel, Nina K. Steckel, U. W. Schaefer, Hellmut Ottinger, Rudolf Peceny, Markus Ditschkowski, Hans Grosse‐Wilde and H. Hirche and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Ahmet Elmaağaclı

80 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ahmet Elmaağaclı Germany	31	1.8k	1.1k	576	468	432	82	2.8k
Hisashi Gondo Japan	29	1.5k 0.8×	1.1k 1.0×	792 1.4×	542 1.2×	415 1.0×	79	2.9k
Voravit Ratanatharathorn United States	29	2.0k 1.2×	1.1k 1.0×	857 1.5×	537 1.1×	350 0.8×	140	3.6k
Peter Bardy Australia	28	1.0k 0.6×	957 0.8×	555 1.0×	562 1.2×	387 0.9×	93	2.5k
JH Antin United States	24	1.8k 1.0×	924 0.8×	566 1.0×	227 0.5×	475 1.1×	50	2.8k
Yoshihisa Kodera Japan	34	2.6k 1.5×	1.8k 1.6×	865 1.5×	359 0.8×	584 1.4×	143	4.1k
Nathalie Dhédin France	29	1.4k 0.8×	823 0.7×	905 1.6×	905 1.9×	365 0.8×	127	3.2k
Anthony P. Schwarer Australia	29	2.1k 1.2×	886 0.8×	591 1.0×	535 1.1×	378 0.9×	119	3.3k
Carmella van de Ven United States	31	1.1k 0.6×	1.1k 1.0×	891 1.5×	537 1.1×	320 0.7×	151	2.9k
Atsushi Wake Japan	26	1.2k 0.7×	694 0.6×	656 1.1×	281 0.6×	446 1.0×	125	2.2k
Rudolf Trenschel Germany	27	1.2k 0.7×	733 0.6×	603 1.0×	632 1.4×	174 0.4×	64	2.1k

Countries citing papers authored by Ahmet Elmaağaclı

Since Specialization

Citations

This map shows the geographic impact of Ahmet Elmaağaclı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmet Elmaağaclı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmet Elmaağaclı more than expected).

Fields of papers citing papers by Ahmet Elmaağaclı

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmet Elmaağaclı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmet Elmaağaclı. The network helps show where Ahmet Elmaağaclı may publish in the future.

Co-authorship network of co-authors of Ahmet Elmaağaclı

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmet Elmaağaclı. A scholar is included among the top collaborators of Ahmet Elmaağaclı based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmet Elmaağaclı. Ahmet Elmaağaclı is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coutre, Philipp le, Andreas Burchert, Susanne Saußele, et al.. (2025). Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trial. Acta Haematologica. 1–13.

Ruggeri, Annalisa, Myriam Labopin, Andrea Bacigalupo, et al.. (2018). Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. Journal of Hematology & Oncology. 11(1). 40–40. 97 indexed citations

Ruggeri, Annalisa, Myriam Labopin, Boris V. Afanasyev, et al.. (2017). Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT. Blood. 130. 215–215. 6 indexed citations

Elmaağaclı, Ahmet, Markus Ditschkowski, Nina K. Steckel, et al.. (2014). Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GVHD. Bone Marrow Transplantation. 49(6). 800–805. 8 indexed citations

Saner, Fuat H., Dieter P. Hoyer, Peter Rath, et al.. (2014). A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients. BMC Gastroenterology. 14(1). 4–4. 7 indexed citations

Wolff, Daniel, Francis Ayuk, Ahmet Elmaağaclı, et al.. (2013). Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers. Biology of Blood and Marrow Transplantation. 19(5). 767–776. 30 indexed citations

Koldehoff, Michael, Johannes L. Zakrzewski, Dietrich W. Beelen, & Ahmet Elmaağaclı. (2013). Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Therapy. 20(7). 421–427. 18 indexed citations

Elmaağaclı, Ahmet, Nina K. Steckel, Michael Koldehoff, et al.. (2011). Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 118(5). 1402–1412. 248 indexed citations

Elmaağaclı, Ahmet, Michael Koldehoff, Olfert Landt, & Dietrich W. Beelen. (2008). Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplantation. 41(9). 821–826. 51 indexed citations

10.

Díaz-Carballo, David, et al.. (2008). Nemorosone blocks proliferation and induces apoptosis in leukemia cells. International Journal of Clinical Pharmacology and Therapeutics. 46(8). 428–439. 29 indexed citations

11.

Beelen, Dietrich W., Tanja Gromke, Rudolf Trenschel, et al.. (2008). Treosulfan Compared to Total Body Irradiation-Based Preparative Regimens Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia : A Retrospective Long-Term Study.. Blood. 112(11). 2149–2149. 2 indexed citations

12.

Ditschkowski, Markus, Ahmet Elmaağaclı, Rudolf Trenschel, et al.. (2007). T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica. 92(4). 558–561. 39 indexed citations

13.

Steckel, Nina K., Michael Koldehoff, Markus Ditschkowski, Dietrich W. Beelen, & Ahmet Elmaağaclı. (2007). Use of the Activating Gene Mutation of the Tyrosine Kinase (VAL617Phe) JAK2 as a Minimal Residual Disease Marker in Patients With Myelofibrosis and Myeloid Metaplasia After Allogeneic Stem Cell Transplantation. Transplantation. 83(11). 1518–1520. 22 indexed citations

14.

Elmaağaclı, Ahmet, Michael Koldehoff, Nina K. Steckel, et al.. (2007). Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplantation. 40(7). 659–664. 20 indexed citations

15.

Koldehoff, Michael, Johannes L. Zakrzewski, Ludger Klein‐Hitpaß, Dietrich W. Beelen, & Ahmet Elmaağaclı. (2007). Gene profiling of growth factor independence 1B gene (Gfi-1B) in leukemic cells. International Journal of Hematology. 87(1). 39–47. 12 indexed citations

16.

Hertenstein, Bernd, Lothar Hambach, Andrea Bacigalupo, et al.. (2005). Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).. PubMed. 90(7). 969–75. 113 indexed citations

17.

Elmaağaclı, Ahmet, Hellmut Ottinger, Michael Koldehoff, et al.. (2005). Reduced Risk for Molecular Disease in Patients with Chronic Myeloid Leukemia after Transplantation from a KIR-Mismatched Donor. Transplantation. 79(12). 1741–1747. 31 indexed citations

18.

Koldehoff, Michael, Ahmet Elmaağaclı, Nina K. Steckel, et al.. (2005). Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease. 7(3-4). 137–145. 4 indexed citations

19.

Elmaağaclı, Ahmet, Meinhard Hahn, Bertram Opalka, et al.. (2001). Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR‐ABL fusion transcripts detected using a new real‐time polymerase chain reaction method. British Journal of Haematology. 113(4). 1072–1075. 34 indexed citations

20.

Trarbach, Tanja, Walter Bardenheuer, Ahmet Elmaağaclı, et al.. (2000). Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments. Cytotherapy. 2(6). 429–438. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact